<table id="_Refid_64833565-0087-4a0c-b023-05cd64832" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5 Drug Interactions: Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of Nevirapine (All Interaction Trials Were Conducted in HIV-1 Positive Subjects)</caption>
<col width="22%"></col>
<col width="16%"></col>
<col width="12%"></col>
<col width="12%"></col>
<col width="13%"></col>
<col width="12%"></col>
<col width="12%"></col>
<tbody>
<tr>
<td stylecode="Rrule Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">Coadministered Drug</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Toprule ">
<paragraph>
<content stylecode="bold">Dose of Coadministered Drug</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Toprule ">
<paragraph>
<content stylecode="bold">Dose Regimen of Nevirapine</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Toprule ">
<paragraph>
<content stylecode="bold">n</content>
</paragraph>
</td>
<td align="center" colspan="3" stylecode="Rrule Botrule Toprule ">
<paragraph>
<content stylecode="bold">% Change of Coadministered Drug Pharmacokinetic Parameters (90% CI)</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Antiretrovirals</content>
</paragraph>
</td>
<td stylecode="Rrule Botrule "></td>
<td stylecode="Rrule Botrule "></td>
<td stylecode="Rrule Botrule "></td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<content stylecode="bold">AUC</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<content stylecode="bold">C<sub>max</sub>
</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<content stylecode="bold">C<sub>min</sub>
</content>
</paragraph>
</td>
</tr>
<tr>
<td rowspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>Atazanavir/Ritonavir<footnote id="_Refid-d290b38a-9752-424f-8cc3-4249acce9">For information regarding clinical recommendations, <content stylecode="italics">see <linkhtml href="#i4i_interactions_id_556b908b-c1bf-4d0c-b78d-558f3e2f2188">Drug Interactions (7)</linkhtml>
</content>.</footnote>
<footnote id="_Refid-d6b85222-fec4-438e-8ee7-ec56a9a69">Parallel group design; n = 23 for atazanavir/ritonavir + nevirapine, n = 22 for atazanavir/ritonavir without nevirapine. Changes in atazanavir PK are relative to atazanavir/ritonavir 300 mg/100 mg alone.</footnote>
</paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>300 mg/100 mg QD day 4 to 13, then 400 mg/100 mg QD, day 14 to 23</paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>200 mg BID day 1 to 23. Subjects were treated with nevirapine prior to trial entry.</paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>23</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<content stylecode="underline">Atazanavir </content>
<br/>
<content stylecode="underline">300 mg/100 mg</content>
<br/>
<br/>↓42 <br/>(↓52 to ↓29)</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<content stylecode="underline">Atazanavir </content>
<br/>
<content stylecode="underline">300 mg/100 mg</content>
<br/>
<br/>↓28 <br/>(↓40 to ↓14)</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<content stylecode="underline">Atazanavir </content>
<br/>
<content stylecode="underline">300 mg/100 mg</content>
<br/>
<br/>↓72 <br/>(↓80 to ↓60)</paragraph>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="underline">Atazanavir </content>
<br/>
<content stylecode="underline">400 mg/100 mg</content>
<br/>
<br/>↓19 <br/>(↓35 to ↑2)</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<content stylecode="underline">Atazanavir </content>
<br/>
<content stylecode="underline">400 mg/100 mg</content>
<br/>
<br/>↑2 <br/>(↓15 to ↑24)</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<content stylecode="underline">Atazanavir </content>
<br/>
<content stylecode="underline">400 mg/100 mg</content>
<br/>
<br/>↓59 <br/>(↓73 to ↓40)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Darunavir/Ritonavir<footnote id="_Refid-cd2b0766-0a6d-4fe3-ac44-7d476fd32">Based on between-trial comparison.</footnote>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>400 mg/100 mg BID</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg BID</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>8</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑24 <br/>(↓3 to ↑57)</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑40 <br/>(↑14 to ↑73)</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑2 <br/>(↓21 to ↑32)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Didanosine</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>100 mg to 150 mg BID</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>18</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<footnote id="_Refid-b7af9a6a-b03d-4c18-9105-58a4f6873">C<sub>min</sub> below detectable level of the assay</footnote>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Efavirenz<footnoteref idref="_Refid-d290b38a-9752-424f-8cc3-4249acce9"></footnoteref>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>600 mg QD </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 400 mg QD x 14 days </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>17 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓28 <br/>(↓34 to ↓14) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓12 <br/>(↓23 to ↑1) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓32 <br/>(↓35 to ↓19) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Fosamprenavir </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>1400 mg BID </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg BID. Subjects were treated with nevirapine prior to trial entry. </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>17 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓33 <br/>(↓45 to ↓20) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓25 <br/>(↓37 to ↓10) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓35 <br/>(↓50 to ↓15) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Fosamprenavir/Ritonavir </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>700 mg/100 mg BID </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg BID. Subjects were treated with nevirapine prior to trial entry </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>17 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓11 <br/>(↓23 to ↑3) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓19 <br/>(↓32 to ↓4) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Indinavir <footnoteref idref="_Refid-d290b38a-9752-424f-8cc3-4249acce9"></footnoteref>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>800 mg q8H </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>19 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓31 <br/>(↓39 to ↓22) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓15 <br/>(↓24 to ↓4) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓44 <br/>(↓53 to ↓33) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Lopinavir<footnoteref idref="_Refid-d290b38a-9752-424f-8cc3-4249acce9"></footnoteref>
<footnote id="_Refid-5d9adf7e-432c-4c3b-bbd8-735d2e20d">Pediatric subjects ranging in age from 6 months to 12 years</footnote>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>300 mg/75 mg/m<sup>2</sup> (lopinavir/ ritonavir)<footnoteref idref="_Refid-5d9adf7e-432c-4c3b-bbd8-735d2e20d"></footnoteref>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>7 mg/kg or 4 mg/kg QD x 2 weeks; BID x 1 week </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>12, 15<footnote id="_Refid-8500f460-4306-40b7-8bc8-34fa97138">Parallel group design; n for nevirapine + lopinavir/ritonavir, n for lopinavir/ritonavir alone.</footnote>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓22 <br/>(↓44 to ↑9) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓14 <br/>(↓36 to ↑16) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓55 <br/>(↓75 to ↓19) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Lopinavir <footnoteref idref="_Refid-d290b38a-9752-424f-8cc3-4249acce9"></footnoteref>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>400 mg/100 mg BID (lopinavir/ ritonavir) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID <br/>&gt; 1 year </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>22, 19<footnoteref idref="_Refid-8500f460-4306-40b7-8bc8-34fa97138"></footnoteref>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓27 <br/>(↓47 to ↓2) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓19 <br/>(↓38 to ↑5) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓51 <br/>(↓72 to ↓26) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Maraviroc<footnote id="_Refid-3d1b9121-1290-4d64-a052-b0f16a842">Based on historical controls.</footnote>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>300 mg SD </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg BID </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>8 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑1 <br/>(↓35 to ↑55) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑54 <br/>(↓6 to ↑151) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Nelfinavir <footnoteref idref="_Refid-d290b38a-9752-424f-8cc3-4249acce9"></footnoteref>
</paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>750 mg TID </paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>23 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓32 <br/>(↓50 to ↑5) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Nelfinavir-M8 metabolite</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓62 <br/>(↓70 to ↓53) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓59 <br/>(↓68 to ↓48) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓66 <br/>(↓74 to ↓55) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Ritonavir </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>600 mg BID </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>18 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Stavudine </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>30 mg to 40 mg BID </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>22 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<footnoteref idref="_Refid-b7af9a6a-b03d-4c18-9105-58a4f6873"></footnoteref>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Zalcitabine </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>0.125 mg to <br/>0.25 mg TID </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>6 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<footnoteref idref="_Refid-b7af9a6a-b03d-4c18-9105-58a4f6873"></footnoteref>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Zidovudine </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>100 mg to 200 mg TID </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>11 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓28 <br/>(↓40 to ↓4) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓30 <br/>(↓51 to ↑14) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<footnoteref idref="_Refid-b7af9a6a-b03d-4c18-9105-58a4f6873"></footnoteref>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Other Medications </content>
</paragraph>
</td>
<td stylecode="Rrule Botrule "></td>
<td stylecode="Rrule Botrule "></td>
<td stylecode="Rrule Botrule "></td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<content stylecode="bold">AUC </content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<content stylecode="bold">C<sub>max</sub>
</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<content stylecode="bold">C<sub>min</sub>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Clarithromycin <footnoteref idref="_Refid-d290b38a-9752-424f-8cc3-4249acce9"></footnoteref>
</paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>500 mg BID </paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>15 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓31 <br/>(↓38 to ↓24) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓23 <br/>(↓31 to ↓14) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓56 <br/>(↓70 to ↓36) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Metabolite <br/>14-OH-clarithromycin </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑42 <br/>(↑16 to ↑73) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑47 <br/>(↑21 to ↑80) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
</tr>
<tr>
<td rowspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>Ethinyl estradiol <footnoteref idref="_Refid-d290b38a-9752-424f-8cc3-4249acce9"></footnoteref>
<br/>
<br/>and <br/>
<br/>Norethindrone <footnoteref idref="_Refid-d290b38a-9752-424f-8cc3-4249acce9"></footnoteref>
</paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>0.035 mg (as Ortho-Novum<sup>®**</sup> 1/35) <br/>
<br/>
<br/>1 mg (as Ortho-Novum<sup>®**</sup> 1/35) </paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>10 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓20 <br/>(↓33 to ↓3)<br/>
<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<footnoteref idref="_Refid-b7af9a6a-b03d-4c18-9105-58a4f6873"></footnoteref>
</paragraph>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>↓19 <br/>(↓30 to ↓7) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓16 <br/>(↓27 to ↓3) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<footnoteref idref="_Refid-b7af9a6a-b03d-4c18-9105-58a4f6873"></footnoteref>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Depomedroxy-<br/>progesterone acetate </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>150 mg every 3 months </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>32 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Fluconazole </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>19 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Ketoconazole <footnoteref idref="_Refid-d290b38a-9752-424f-8cc3-4249acce9"></footnoteref>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>400 mg QD </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>21 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓72 <br/>(↓80 to ↓60) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↓44 <br/>(↓58 to ↓27) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<footnoteref idref="_Refid-b7af9a6a-b03d-4c18-9105-58a4f6873"></footnoteref>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Methadone <footnoteref idref="_Refid-d290b38a-9752-424f-8cc3-4249acce9"></footnoteref>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>Individual Subject Dosing </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID ≥ 7 days </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>9 </paragraph>
</td>
<td align="center" colspan="3" stylecode="Rrule Botrule ">
<paragraph>In a controlled pharmacokinetic trial with nine subjects receiving chronic methadone to whom steady-state nevirapine therapy was added, the clearance of methadone was increased by 3-fold, resulting in symptoms of withdrawal, requiring dose adjustments in 10 mg segments, in seven of the nine subjects. Methadone did not have any effect on nevirapine clearance. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Rifabutin <footnoteref idref="_Refid-d290b38a-9752-424f-8cc3-4249acce9"></footnoteref>
</paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>150 mg or 300 mg QD </paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" rowspan="2" stylecode="Rrule Botrule ">
<paragraph>19 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑17 <br/>(↓2 to ↑40) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑28 <br/>(↑9 to ↑51) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Metabolite 25-O-desacetyl-rifabutin </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑24 <br/>(↓16 to ↑84) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑29 <br/>(↓2 to ↑68) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑22 <br/>(↓14 to ↑74) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Rifampin <footnoteref idref="_Refid-d290b38a-9752-424f-8cc3-4249acce9"></footnoteref>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>600 mg QD </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>14 </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↑11 <br/>(↓4 to ↑28) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>↔</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule ">
<paragraph>
<footnoteref idref="_Refid-b7af9a6a-b03d-4c18-9105-58a4f6873"></footnoteref>
</paragraph>
</td>
</tr>
<tr>
<td colspan="7" stylecode="Rrule Botrule Lrule ">
<paragraph>↑ = Increase, ↓ = Decrease, ↔ = No Effect</paragraph>
</td>
</tr>
</tbody>
</table>